The Phase 1/2 ACCEPT Trial: Concurrent Cetuximab and Intensity Modulated Radiation Therapy with Carbon Ion Boost for Adenoid Cystic Carcinoma of the Head and Neck
Published in
International Journal of Radiation Oncology, Biology, Physics, October 2019
This research output has an Altmetric Attention Score of 2. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 15 February 2020.
All research outputs
#24,423,449
of 34,779,718 outputs
Outputs from International Journal of Radiation Oncology, Biology, Physics
#11,976
of 15,756 outputs
Outputs of similar age
#261,882
of 394,139 outputs
Outputs of similar age from International Journal of Radiation Oncology, Biology, Physics
#157
of 289 outputs
Altmetric has tracked 34,779,718 research outputs across all sources so far. This one is in the 27th percentile – i.e., 27% of other outputs scored the same or lower than it.
So far Altmetric has tracked 15,756 research outputs from this source. They typically receive more attention than average, with a mean Attention Score of 8.4. This one is in the 22nd percentile – i.e., 22% of its peers scored the same or lower than it.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 394,139 tracked outputs that were published within six weeks on either side of this one in any source. This one is in the 31st percentile – i.e., 31% of its contemporaries scored the same or lower than it.
We're also able to compare this research output to 289 others from the same source and published within six weeks on either side of this one. This one is in the 43rd percentile – i.e., 43% of its contemporaries scored the same or lower than it.
